27890470|t|sGC stimulators: Evidence for riociguat beyond groups 1 and 4 pulmonary hypertension
27890470|a|Pulmonary hypertension (PH) is a chronic cardiopulmonary disorder that if left untreated, progresses rapidly and is ultimately fatal. The World Health Organization (WHO) has classified PH into 5 distinct groups according to pathophysiology, hemodynamic characteristics, and clinical presentation. Dysfunction in the nitric oxide (NO) pathway plays a key role in the pulmonary hypertension disease process, including in WHO Groups 2 and 3 PH. PH is associated with endothelial dysfunction, impaired synthesis of NO, and insufficient stimulation of the NO-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway, which reduces cGMP production. cGMP regulates vascular tone, cellular proliferation, inflammation, and fibrosis and its depletion can lead to a variety of abnormalities, including pulmonary vasoconstriction, impaired vascular remodeling, and in situ thrombosis. This review will examine a novel class of drugs called sGC stimulators which directly stimulate sGC independently of NO, leading to increased production of cGMP.
27890470	0	15	sGC stimulators	T121	C3819023
27890470	17	25	Evidence	T078	C3887511
27890470	30	39	riociguat	T109,T121	C2717561
27890470	47	55	groups 1	T047	C2973725
27890470	60	84	4 pulmonary hypertension	T047	C2363973
27890470	85	107	Pulmonary hypertension	T046	C0020542
27890470	109	111	PH	T046	C0020542
27890470	118	125	chronic	T079	C0205191
27890470	126	150	cardiopulmonary disorder	T047	C0034072
27890470	175	185	progresses	T169	C1272688
27890470	186	193	rapidly	T080	C0456962
27890470	212	217	fatal	T080	C1302234
27890470	223	248	World Health Organization	T093	C0043237
27890470	250	253	WHO	T093	C0043237
27890470	259	269	classified	T185	C0008902
27890470	270	272	PH	T046	C0020542
27890470	289	295	groups	T078	C0441833
27890470	309	324	pathophysiology	T169	C0031847
27890470	326	337	hemodynamic	T042	C0019010
27890470	338	353	characteristics	T080	C1521970
27890470	359	380	clinical presentation	T170	C2708283
27890470	382	393	Dysfunction	T077	C3887504
27890470	401	426	nitric oxide (NO) pathway	T044	C1518332
27890470	451	473	pulmonary hypertension	T046	C0020542
27890470	474	489	disease process	T046	C0030660
27890470	504	507	WHO	T093	C0043237
27890470	508	516	Groups 2	T047	C3532326
27890470	521	525	3 PH	T047	C3698136
27890470	527	529	PH	T046	C0020542
27890470	533	548	associated with	T080	C0332281
27890470	549	572	endothelial dysfunction	T047	C0856169
27890470	574	582	impaired	T169	C0221099
27890470	583	598	synthesis of NO	T044	C1157570
27890470	604	616	insufficient	T080	C0231180
27890470	617	628	stimulation	T070	C1948023
27890470	636	716	NO-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway	T044	C3271755
27890470	724	731	reduces	T080	C0392756
27890470	732	736	cGMP	T114,T123	C0018338
27890470	737	747	production	T169	C0205245
27890470	749	753	cGMP	T114,T123	C0018338
27890470	764	777	vascular tone	T042	C0042396
27890470	779	801	cellular proliferation	T043	C0596290
27890470	803	815	inflammation	T046	C0021368
27890470	821	829	fibrosis	T046	C0016059
27890470	838	847	depletion	T169	C0333668
27890470	873	886	abnormalities	T033	C1704258
27890470	898	924	pulmonary vasoconstriction	T033	C1867424
27890470	926	934	impaired	T169	C0221099
27890470	935	954	vascular remodeling	T042	C3850148
27890470	960	978	in situ thrombosis	T033	C1867429
27890470	997	1004	examine	T033	C0332128
27890470	1007	1012	novel	T080	C0205314
27890470	1022	1027	drugs	T121	C0013227
27890470	1035	1050	sGC stimulators	T121	C3819023
27890470	1066	1075	stimulate	T070	C1948023
27890470	1076	1079	sGC	T116,T126,T192	C1097411
27890470	1080	1093	independently	T169	C0332291
27890470	1097	1099	NO	T121,T123,T197	C0028128
27890470	1112	1121	increased	T081	C0205217
27890470	1122	1132	production	T169	C0205245
27890470	1136	1140	cGMP	T114,T123	C0018338